The Luterion group has established GMP-grade investigational medicinal product manufacturing capabilities supported by EU QP declaration. Its global development network is designed to support translational research, nonclinical development, clinical coordination, and future manufacturing expansion.
LUTERION also collaborates with academic, clinical, and research institutions across Europe to support animal studies, human ex vivo research, organoid models, and multi-omics investigations.
Parent IP-holding company, BSL-2 mito-immune research infrastructure, company-affiliated research institute, and GMP-grade investigational product manufacturing capabilities through affiliated operations.
EU nonclinical and clinical coordination, joint R&D activities, and future manufacturing and GLP/GMP laboratory expansion.
US-facing development and partnering strategy for selected programs, including H5N1 preparedness.
Academic and clinical collaborations supporting animal studies, human ex vivo research, organoid models, genomics, and proteomics.